ERBB2 and neoplasm: demonstrated in vivo tumor accumulation ranging from 3% up to 15% of the total administered dose of anti‐HER2‐coated docetaxel‐liposomes in MDA‐MB‐453 and MDA‐MB‐231 tumor‐bearing mice.